Categories: CancerDiagnosticsNews

Circulogene Launches LungLifeAI® Nationally Through Primary Care Channel

PENSACOLA, Fla., June 24, 2025 /PRNewswire/ — Circulogene, a leading provider of precision diagnostics for lung cancer, has announced the national commercial launch of LungLifeAI®, now available across its expanding base of primary care clients.

Circulogene Launches LungLifeAI® Nationally Through Primary Care Channel

LungLifeAI® is an AI-powered blood test that supports early lung cancer detection by helping physicians assess malignancy risk in indeterminate pulmonary nodules (IPNs) found on CT scans. With an 80% positive predictive value, the test provides physicians with greater confidence in determining whether a biopsy or further evaluation is warranted.

“This marks a major step forward in our mission to transform early lung cancer detection,” said Mike Mullen, CEO of Circulogene. “Primary care physicians are often the first to identify risk. LungLifeAI® gives them a powerful, accessible tool to act quickly—and potentially save lives.”

This launch highlights the industry’s growing focus on earlier intervention. For lung cancer—where screening pathways remain limited—LungLifeAI® offers a valuable option to close the gap in front-line clinical decision-making.

The test requires only a standard blood draw and delivers results quickly, enhancing access for physicians and patients alike. “This isn’t just innovation in diagnostics—it’s innovation in access,” added Mullen.

LungLifeAI® uses proprietary AI algorithms to analyze circulating genetically abnormal cells (CGACs) in the blood, helping identify early cancer risk even when nodules appear small or ambiguous. The result is faster, more informed decisions that may reduce diagnostic delays and improve patient outcomes.

About Circulogene

Circulogene is a Birmingham-based precision medicine company advancing early-stage cancer detection through innovative liquid biopsy solutions. The company operates a CAP- and CLIA-certified lab and introduced the first blood-based PD-L1 test to market. Learn more at www.circulogene.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/circulogene-launches-lunglifeai-nationally-through-primary-care-channel-302489978.html

SOURCE Circuologene

Staff

Recent Posts

Vent Creativity Appoints Paul Abrams as Vice President of Sales to Lead Commercial Growth

NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…

18 hours ago

AEON Clinic Announces Next Generation Medicine Congress 2026 Event: A Global Convergence on Human Longevity in Dubai

AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…

18 hours ago

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

2 days ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

2 days ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

2 days ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

2 days ago